Bio-Path's Cash Dries Up Amid Soaring R&D Costs, Raising Going Concern Doubts

TL;DR

**BPTH is bleeding cash with zero on hand, making a dilutive capital raise or potential collapse imminent.**

AI Summary

BIO-PATH HOLDINGS, INC. reported a significant increase in net loss for the three and six months ended June 30, 2025, primarily driven by increased research and development expenses. The net loss for the three months ended June 30, 2025, was $4.597 million, compared to $1.869 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $7.449 million, a substantial increase from $5.026 million in 2024. Research and development expenses surged to $4.048 million for the three months ended June 30, 2025, up from $1.873 million in 2024, and to $6.025 million for the six months ended June 30, 2025, from $4.161 million in 2024. The company's cash balance plummeted from $1.173 million at December 31, 2024, to $0 at June 30, 2025, indicating a severe liquidity crunch. Total assets decreased from $3.883 million at December 31, 2024, to $746 thousand at June 30, 2025, while total liabilities increased from $3.729 million to $7.904 million in the same period. The company explicitly stated that its available cash of $0.0 million at June 30, 2025, will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

This filing signals a critical juncture for BIO-PATH HOLDINGS, INC. and its stakeholders. For investors, the complete depletion of cash and the explicit 'going concern' warning mean immediate and significant dilution is highly probable through further equity raises, or even potential bankruptcy if funding isn't secured. Employees face job insecurity as the company may be forced to curtail programs. Customers and the broader market, particularly those awaiting the company's RNAi nanoparticle drug candidates for oncology and obesity, could see significant delays or even abandonment of promising drug development, impacting future treatment options and competitive dynamics in the biotech space. The company's ability to compete effectively in the highly competitive pharmaceutical and biotechnology industry is severely hampered by its financial instability.

Risk Assessment

Risk Level: high — The risk level is high due to the company's explicit statement that its available cash of $0.0 million at June 30, 2025, will not be sufficient to fund liquidity for the next 12 months, leading to 'substantial doubt' about its ability to continue as a going concern. This is compounded by a significant increase in net loss to $7.449 million for the six months ended June 30, 2025, and a rise in total liabilities to $7.904 million, far exceeding its total assets of $746 thousand.

Analyst Insight

Investors should avoid BPTH given the severe liquidity crisis and explicit going concern warning. Current shareholders should consider exiting their positions, as significant dilution from future capital raises or even potential insolvency appears highly likely in the near term.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$746K

total Debt

$7.904M

net Income

-$7.449M

eps

-$0.97

gross Margin

N/A

cash Position

$0.0M

revenue Growth

N/A

Key Numbers

• $0.0M — Cash (Cash balance at June 30, 2025, down from $1.173M at Dec 31, 2024, indicating severe liquidity issues.)
• $7.449M — Net Loss (Six Months) (Increased from $5.026M in the prior year, reflecting higher operating expenses.)
• $6.025M — Research and Development Expenses (Six Months) (Increased from $4.161M in the prior year, driving higher operating losses.)
• $7.158M — Total Shareholders' (Deficit) Equity (Negative equity at June 30, 2025, a significant decline from positive $154K at Dec 31, 2024.)
• $7.904M — Total Liabilities (Increased from $3.729M at Dec 31, 2024, further straining the balance sheet.)
• 8,307,892 — Common Shares Outstanding (As of August 13, 2025, indicating potential for further dilution if capital is raised.)

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant
• $4.597 million (dollar_amount) — Net loss for three months ended June 30, 2025
• $1.869 million (dollar_amount) — Net loss for three months ended June 30, 2024
• $7.449 million (dollar_amount) — Net loss for six months ended June 30, 2025
• $5.026 million (dollar_amount) — Net loss for six months ended June 30, 2024
• $0.0 million (dollar_amount) — Cash at June 30, 2025
• $1.173 million (dollar_amount) — Cash at December 31, 2024
• $746 thousand (dollar_amount) — Total Assets at June 30, 2025
• $3.883 million (dollar_amount) — Total Assets at December 31, 2024
• $7.904 million (dollar_amount) — Total Liabilities at June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has $0.0 million in cash as of June 30, 2025, and explicitly states this is insufficient to fund liquidity and capital expenditure requirements for the next 12 months. This raises substantial doubt about its ability to continue as a going concern.
• Deteriorating Balance Sheet [high — financial]: Total assets decreased from $3.883 million at December 31, 2024, to $746 thousand at June 30, 2025. Concurrently, total liabilities increased from $3.729 million to $7.904 million, resulting in a significant negative shareholders' deficit of $7.158 million.
• Surging Operating Expenses [high — financial]: Research and development expenses increased significantly to $6.025 million for the six months ended June 30, 2025, up from $4.161 million in the prior year. This surge in R&D, coupled with other operating expenses, contributed to a net loss of $7.449 million for the period.
• Increased Net Loss [high — financial]: The net loss for the six months ended June 30, 2025, was $7.449 million, a substantial increase from $5.026 million in the same period of 2024. This widening loss exacerbates the company's financial distress.
• Potential Shareholder Dilution [medium — financial]: With 8,307,892 common shares outstanding as of August 13, 2025, any future capital raises to address liquidity issues could lead to significant dilution for existing shareholders.

Industry Context

BIO-PATH HOLDINGS, INC. operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies vying for funding and market share through innovation and clinical trial success. Trends include a focus on novel therapeutics and personalized medicine, but also increasing scrutiny on drug pricing and development efficiency.

Regulatory Implications

As a biotechnology company, BIO-PATH HOLDINGS, INC. is subject to stringent regulations from bodies like the FDA. Failure to meet regulatory standards in drug development, clinical trials, or manufacturing can lead to significant delays, increased costs, or outright rejection of products. The company's current financial distress could also impact its ability to fund necessary regulatory compliance activities.

What Investors Should Do

1. Monitor cash burn rate and future funding announcements closely.
2. Evaluate the long-term viability of the R&D pipeline.
3. Assess the risk of significant dilution.
4. Consider the going concern warning.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported a severe liquidity crunch with $0.0 million cash, a substantial increase in net loss to $7.449 million for the six months, and a deteriorating balance sheet, raising going concern doubts.
• 2025-06-30: Balance Sheet Date — Total assets decreased to $746 thousand, while total liabilities increased to $7.904 million, resulting in a negative shareholders' deficit of $7.158 million.
• 2025-06-30: Statement of Operations Date — Net loss for the six months was $7.449 million, driven by increased R&D expenses of $6.025 million.
• 2024-12-31: End of Fiscal Year 2024 — Company had $1.173 million in cash, total assets of $3.883 million, and total liabilities of $3.729 million, with a positive shareholders' equity of $154 thousand.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. (Indicates the company has historically incurred more losses than profits, contributing to its current negative equity position.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Warrant liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (Changes in the fair value of these liabilities can impact net income, and their reduction from $434K to $40K reflects a change in their valuation.)

Research and development expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (These expenses have significantly increased, driving the company's net losses and indicating investment in future growth, albeit at a high cost.)

Year-Over-Year Comparison

Compared to the prior year, BIO-PATH HOLDINGS, INC. has experienced a significant deterioration in its financial position. For the six months ended June 30, 2025, the net loss widened to $7.449 million from $5.026 million in 2024, primarily due to a substantial increase in research and development expenses from $4.161 million to $6.025 million. The company's cash position has collapsed from $1.173 million at the end of 2024 to $0.0 million as of June 30, 2025. Total assets have shrunk, while total liabilities have more than doubled, leading to a significant negative shareholders' deficit. New risks related to the company's ability to continue as a going concern are now prominent.

Key Financial Figures

• $0.001 — nding shares of common stock, par value $0.001 per share. Table of Contents Unless

Filing Documents

• bpth-20250630x10q.htm (10-Q) — 928KB
• bpth-20250630xex31.htm (EX-31) — 12KB
• bpth-20250630xex32.htm (EX-32) — 7KB
• 0001558370-25-011591.txt ( ) — 3801KB
• bpth-20250630.xsd (EX-101.SCH) — 33KB
• bpth-20250630_cal.xml (EX-101.CAL) — 33KB
• bpth-20250630_def.xml (EX-101.DEF) — 125KB
• bpth-20250630_lab.xml (EX-101.LAB) — 250KB
• bpth-20250630_pre.xml (EX-101.PRE) — 216KB
• bpth-20250630x10q_htm.xml (XML) — 406KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Condensed Consolidated Balance Sheets (Unaudited and not reviewed) 5 Condensed Consolidated Statements of Operations (Unaudited and not reviewed) 6 Condensed Consolidated Statements of Cash Flows (Unaudited and not reviewed) 7 Condensed Consolidated Statements of Shareholders' (Deficit) Equity (Unaudited and not reviewed) 8 Notes to the Unaudited and not Reviewed Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27

- OTHER INFORMATION

PART II - OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30 Signature 31 4 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS BIO-PATH HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) As of June 30, As of December 31, 2025 2024 (unaudited and not reviewed) Assets Current assets Cash $ — $ 1,173 Prepaid drug product 474 1,074 Other current assets 206 1,529 Total current assets 680 3,776 Fixed assets Furniture, fixtures & equipment 1,010 1,077 Less accumulated depreciation ( 1,001 ) ( 1,054 ) 9 23 Right of use operating assets 57 84 Total Assets $ 746 $ 3,883 Liabilities & Shareholders' (Deficit) Equity Current liabilities Accounts payable $ 3,479 $ 1,274 Notes payable 422 — Accrued expenses 3,906 1,938 Lease liabilities 57 83 Total current liabilities 7,864 3,295 Warrant liability 40 434 Total Liabilities 7,904 3,729 Shareholders' (deficit) equity Preferred stock, $ .001 par value; 10,000 shares authorized; no shares issued and outstanding — — Common stock, $ .001 par value; 200,000 shares authorized; 8,308 and 5,768 shares issued and outstanding , respectively 8 6 Additional paid in capital 117,784 117,649 Accumulated deficit ( 124,950 ) ( 117,501 ) Total shareholders' (deficit) equity ( 7,158 ) 154 Total Liabilities & Shareholders' (Deficit) Equity $ 746 $ 3,883 SEE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 5 Table of Contents BIO-PATH HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited and not reviewed) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses Research and development $ 4,048 $ 1,873 $ 6,025 $ 4,161 General and administrative 514 1,165 1,778 2,572 Total operating expenses 4,562 3,038 7,803 6,733 Net operating loss $ ( 4,562 ) $ ( 3,038 ) $ ( 7,803 ) $ ( 6,733 ) Other income (expense

View Full Filing

View this 10-Q filing on SEC EDGAR